Results 21 to 30 of about 9,498 (160)

Safety and efficacy of Sofosbuvir therapy in chronic hepatitis C patients of Peshawar, Khyber Pakhtunkhwa, Pakistan [PDF]

Songklanakarin Journal of Science and Technology (SJST), 2022
This study is designed to monitor the rapid virological response (RVR) for 8 weeks and sustained virological response (SVR) for 12 weeks during Sofosbuvir therapy in chronic hepatitis C patients in Peshawar, KPK, Pakistan.
Muhammad Jawad, Sobia Attaullah, Sanaullah khan, Faheem Ullah, Muhammad Zahid, Faisal Saeed, Ayesha Rizwan, Abdul Wahab   +7 more
doaj   +1 more source

Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form

Future Journal of Pharmaceutical Sciences, 2018
Objective: A simple, specific, accurate and economic reverse phase liquid chromatographic method was developed for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and tablet dosage form.
S.K. Mastanamma, S.K. Chandini, S.K. Reehana, P. Saidulu   +3 more
doaj   +1 more source

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. [PDF]

PLoS Neglected Tropical Diseases, 2019
Yellow fever virus (YFV) is a member of the Flaviviridae family. In Brazil, yellow fever (YF) cases have increased dramatically in sylvatic areas neighboring urban zones in the last few years. Because of the high lethality rates associated with infection
Caroline S de Freitas, Luiza M Higa, Carolina Q Sacramento, André C Ferreira, Patrícia A Reis, Rodrigo Delvecchio, Fabio L Monteiro, Giselle Barbosa-Lima, Harrison James Westgarth, Yasmine Rangel Vieira, Mayara Mattos, Natasha Rocha, Lucas Villas Bôas Hoelz, Rennan Papaleo Paes Leme, Mônica M Bastos, Gisele Olinto L Rodrigues, Carla Elizabeth M Lopes, Celso Martins Queiroz-Junior, Cristiano X Lima, Vivian V Costa, Mauro M Teixeira, Fernando A Bozza, Patrícia T Bozza, Nubia Boechat, Amilcar Tanuri, Thiago Moreno L Souza   +25 more
doaj   +1 more source

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate

Life, 2023
This study retrospectively analyzed the medical records of 602 patients with first-time positive results for the HCV nucleic acid test between 1 May 2021 and 31 March 2023, exploring the association between DAA treatment and SARS-CoV-2 infection.
Chin-Wen Hsu, Wan-Wen Yang, Chia-Yi Hou, I-Jung Feng, Ting-Yi Huang, Pei-Lun Lee, How-Ran Guo, Chien-Yuan Huang, Shih-Bin Su   +8 more
doaj   +1 more source

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Journal of Virus Eradication, 2016
Objectives: Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices.
Andrew Hill, Bryony Simmons, Dzintars Gotham, Joseph Fortunak   +3 more
doaj   +1 more source

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

The Lancet Microbe, 2020
Summary: Background: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy.
Catherine A Chappell, MD, Kimberly K Scarsi, PharmD, Brian J Kirby, PhD, Vithika Suri, MSc, Anuj Gaggar, MD, Debra L Bogen, ProfMD, Ingrid S Macio, PA, Leslie A Meyn, PhD, Katherine E Bunge, MD, Elizabeth E Krans, MD, Sharon L Hillier, ProfPhD   +10 more
doaj   +1 more source

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes

Scientific Reports
Sofosbuvir is one of the crucial drugs used in the treatment of chronic hepatitis C virus (HCV) in adults and children with compensated liver disease, including cirrhosis. It may be used alone or with other drugs.
Rana A. Ali, Eatemad A. Awadalla, Yahia A. Amin, Samer S. Fouad, Maha Abd-El Baki Ahmed, Mohammed H. Hassan, Emaad Abdel-Kahaar, Rehab H. Abdel-Aziz   +7 more
doaj   +1 more source

NOVEL DIRECT ACTING ANTIVIRAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C AND CHRONIC KIDNEY DISEASE STAGE 3 TO STAGE 5D

Pakistan Armed Forces Medical Journal, 2020
Objective: To assess the safety and efficacy of Sofosbuvir based Antiviral regimens for chronic hepatitis C virus infected patients with chronic kidney disease stage 3 to stage 5D on haemodialysis. Study Design: Quasi experimental study.
Nauman Kashif, Zahid Farooq Baig, Shahzad Ashraf   +2 more
doaj  

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir

Journal of Investigative Medicine High Impact Case Reports, 2015
The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes ...
Resmi Premji MD, Nira Roopnarinesingh MD, Nazia Qazi MD, Eric S Nylen MD   +3 more
doaj   +1 more source